Literature DB >> 20638364

Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo.

Toyokazu Sasaki1, Koh-Ichi Nakashiro, Hiroshi Tanaka, Koji Azuma, Hiroyuki Goda, Shingo Hara, Jun Onodera, Ichiro Fujimoto, Nozomu Tanji, Masayoshi Yokoyama, Hiroyuki Hamakawa.   

Abstract

The serine/threonine kinase Akt has three highly homologous isoforms in mammals: Akt1, Akt2, and Akt3. Recent studies indicate that Akt is often constitutively active in many types of human malignancy. Here we investigated the expression and function of Akt isoforms in human prostatic carcinoma cells. Initially, we used Western blotting to examine Akt expression in four human prostate cancer cell lines. Next, small-interfering RNAs (siRNAs) specific for Akt isoforms were used to elucidate their role on the in vitro and in vivo growth of prostate cancer cells. Expression of Akt1 and Akt2 was detected in all cells tested, but Akt3 was expressed only in cancer cells that did not express androgen receptors. All synthetic siRNAs against Akt isoforms suppressed their expression and inhibited the growth of cancer cells in vitro. Furthermore, atelocollagen-mediated systemic administration of siRNAs significantly reduced the growth of tumors that had been subcutaneously xenografted. These results suggest that targeting Akt isoforms could be an effective treatment for prostate cancers. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638364     DOI: 10.1016/j.bbrc.2010.07.045

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals.

Authors:  Shinichiro Inaba; Shunji Nagahara; Naoki Makita; Yuzo Tarumi; Takuji Ishimoto; Seiichi Matsuo; Kenji Kadomatsu; Yoshifumi Takei
Journal:  Mol Ther       Date:  2011-10-25       Impact factor: 11.454

2.  Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay.

Authors:  Demetris C Iacovides; Aimee B Johnson; Nick Wang; Shanta Boddapati; Jim Korkola; Joe W Gray
Journal:  Mol Cell Proteomics       Date:  2013-08-08       Impact factor: 5.911

3.  PTEN-deficient tumors depend on AKT2 for maintenance and survival.

Authors:  Y Rebecca Chin; Xin Yuan; Steven P Balk; Alex Toker
Journal:  Cancer Discov       Date:  2014-05-16       Impact factor: 39.397

4.  Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.

Authors:  Xufen Yu; Jia Xu; Yudao Shen; Kaitlyn M Cahuzac; Kwang-Su Park; Brandon Dale; Jing Liu; Ramon E Parsons; Jian Jin
Journal:  J Med Chem       Date:  2022-02-04       Impact factor: 7.446

5.  Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells.

Authors:  Hui-Ping Lin; Shih Sheng Jiang; Chih-Pin Chuu
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

6.  Effects of atelocollagen formulation containing oligonucleotide on endothelial permeability.

Authors:  Koji Hanai; Takashi Kojima; Mika Ota; Jun Onodera; Norimasa Sawada
Journal:  J Drug Deliv       Date:  2012-03-08

7.  Micro-ribonucleic acid 29b inhibits cell proliferation and invasion and enhances cell apoptosis and chemotherapy effects of cisplatin via targeting of DNMT3b and AKT3 in prostate cancer.

Authors:  Bin Yan; Qiong Guo; Xiao-Xin Nan; Zhao Wang; Zhuo Yin; Lu Yi; Yong-Bao Wei; Yun-Liang Gao; Ke-Qin Zhou; Jin-Rui Yang
Journal:  Onco Targets Ther       Date:  2015-03-04       Impact factor: 4.147

8.  AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2.

Authors:  Hui-Ping Lin; Ching-Yu Lin; Chieh Huo; Yee-Jee Jan; Jen-Chih Tseng; Shih Sheng Jiang; Ying-Yu Kuo; Shyh-Chang Chen; Chih-Ting Wang; Tzu-Min Chan; Jun-Yang Liou; John Wang; Wun-Shaing Wayne Chang; Chung-Ho Chang; Hsing-Jien Kung; Chih-Pin Chuu
Journal:  Oncotarget       Date:  2015-09-29

9.  CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation.

Authors:  Xin Han; Zongbin Liu; Myeong Chan Jo; Kai Zhang; Ying Li; Zihua Zeng; Nan Li; Youli Zu; Lidong Qin
Journal:  Sci Adv       Date:  2015-08-14       Impact factor: 14.136

10.  Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma.

Authors:  Norihiko Tokuzen; Koh-ichi Nakashiro; Hiroshi Tanaka; Kazuki Iwamoto; Hiroyuki Hamakawa
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.